sub:assertion {
  d:DB01079 v:identifier "DB01079" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB01079" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB01079> ;
    dv:drugbank-id "APRD00096" , "DB01079" ;
    dv:x-ahfs <http://bio2rdf.org/ahfs:92:00.00> ;
    dv:x-atc <http://bio2rdf.org/atc:A06AX06> ;
    dv:x-cas <http://bio2rdf.org/cas:189188-57-6> ;
    dv:x-chebi <http://bio2rdf.org/chebi:51043> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:4589305> ;
    dv:x-dpd <http://bio2rdf.org/dpd:2245566> ;
    dv:x-ndc <http://bio2rdf.org/ndc:0078-0355-80> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA130413154> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:5487301> ;
    dv:x-pubchemsubstance <http://bio2rdf.org/pubchem.substance:46506519> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Tegaserod> ;
    dct:description "Tegaserod is a 5-HT4 agonist manufactured by Novartis and used for the management of irritable bowel syndrome and constipation. Its use was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating and constipation associated with irritable bowel syndrome. On March 30, 2007, the U.S. Food and Drug Administration requested that Novartis withdraw Zelnorm from shelves. The FDA alleges a relationship between prescriptions of the drug and increased risks of heart attack or stroke. [Wikipedia]"@en ;
    dct:identifier "drugbank:DB01079" ;
    dct:title "Tegaserod"@en ;
    a dv:Drug ;
    rdfs:label "Tegaserod [drugbank:DB01079]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB01079> , <http://www.drugs.com/cdi/tegaserod.html> , <http://www.rxlist.com/cgi/generic3/zelnorm.htm> .
}